Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Buprenorphine: dose-related effects on cocaine and opioid use in cocaine-abusing opioid-dependent humans.

Schottenfeld RS, Pakes J, Ziedonis D, Kosten TR.

Biol Psychiatry. 1993 Jul 1-15;34(1-2):66-74.

PMID:
8373940
2.

Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients.

Eissenberg T, Johnson RE, Bigelow GE, Walsh SL, Liebson IA, Strain EC, Stitzer ML.

Drug Alcohol Depend. 1997 Apr 14;45(1-2):81-91.

PMID:
9179510
3.

Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse.

Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR.

Arch Gen Psychiatry. 1997 Aug;54(8):713-20.

PMID:
9283506
4.

Acute interactions of buprenorphine with intravenous cocaine and morphine: an investigational new drug phase I safety evaluation.

Teoh SK, Mendelson JH, Mello NK, Kuehnle J, Sintavanarong P, Rhoades EM.

J Clin Psychopharmacol. 1993 Apr;13(2):87-99.

PMID:
8463453
5.

Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.

Correia CJ, Walsh SL, Bigelow GE, Strain EC.

Psychopharmacology (Berl). 2006 Dec;189(3):297-306. Epub 2006 Sep 30.

PMID:
17013637
6.
7.

Plasma concentrations of buprenorphine 24 to 72 hours after dosing.

Chawarski MC, Schottenfeld RS, O'Connor PG, Pakes J.

Drug Alcohol Depend. 1999 Jun 1;55(1-2):157-63.

PMID:
10402160
8.

An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence.

Rothman RB, Gorelick DA, Heishman SJ, Eichmiller PR, Hill BH, Norbeck J, Liberto JG.

J Subst Abuse Treat. 2000 Apr;18(3):277-81.

PMID:
10742642
9.

Opioid effects and opioid withdrawal during a 24 h dosing interval in patients maintained on buprenorphine.

Lopatko OV, White JM, Huber A, Ling W.

Drug Alcohol Depend. 2003 Apr 1;69(3):317-22.

PMID:
12633918
10.

Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans.

Amass L, Bickel WK, Crean JP, Blake J, Higgins ST.

Psychopharmacology (Berl). 1998 Apr;136(3):217-25.

PMID:
9566806
11.

Naltrexone and buprenorphine combination in the treatment of opioid dependence.

Gerra G, Fantoma A, Zaimovic A.

J Psychopharmacol. 2006 Nov;20(6):806-14. Epub 2006 Jan 9.

PMID:
16401652
12.

Buprenorphine treatment for opioid dependence: the relative efficacy of daily, twice and thrice weekly dosing.

Marsch LA, Bickel WK, Badger GJ, Jacobs EA.

Drug Alcohol Depend. 2005 Feb 14;77(2):195-204.

PMID:
15664721
13.

Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients.

Bickel WK, Amass L, Crean JP, Badger GJ.

Psychopharmacology (Berl). 1999 Sep;146(2):111-8.

PMID:
10525745
14.

Buprenorphine effects on morphine- and cocaine-induced subjective responses by drug-dependent men.

Teoh SK, Mello NK, Mendelson JH, Kuehnle J, Gastfriend DR, Rhoades E, Sholar W.

J Clin Psychopharmacol. 1994 Feb;14(1):15-27.

PMID:
8151000
15.
16.

Comparison of buprenorphine and methadone maintenance in opiate addicts.

Eder H, Fischer G, Gombas W, Jagsch R, Stühlinger G, Kasper S.

Eur Addict Res. 1998;4 Suppl 1:3-7.

PMID:
9767199
17.

Effects of buprenorphine/naloxone in opioid-dependent humans.

Stoller KB, Bigelow GE, Walsh SL, Strain EC.

Psychopharmacology (Berl). 2001 Mar;154(3):230-42.

PMID:
11351930
18.

Thrice-weekly versus daily buprenorphine maintenance.

Schottenfeld RS, Pakes J, O'Connor P, Chawarski M, Oliveto A, Kosten TR.

Biol Psychiatry. 2000 Jun 15;47(12):1072-9.

PMID:
10862807
19.

Alternate-day dosing during buprenorphine treatment of opioid dependence.

Amass L, Bickel WK, Higgins ST, Badger GJ.

Life Sci. 1994;54(17):1215-28.

PMID:
8164503
20.

Buprenorphine suppresses cocaine self-administration by rhesus monkeys.

Mello NK, Mendelson JH, Bree MP, Lukas SE.

Science. 1989 Aug 25;245(4920):859-62.

PMID:
2772637

Supplemental Content

Support Center